EW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Edwards Lifesciences Corp (EW) is not a strong buy for a beginner investor with a long-term strategy at this time. The technical indicators show bearish trends, and the financial performance reveals declining net income and EPS despite revenue growth. While analysts maintain mostly positive ratings with price targets above the current price, the lack of strong positive catalysts and weak trading sentiment suggest holding off on investment for now.
The MACD is negative (-0.225) and contracting, RSI is neutral at 44.642, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 79.803, with key support at 77.637 and resistance at 81.969.
Analysts maintain mostly Outperform or Buy ratings with price targets ranging from $87 to $110, indicating potential upside. Wolfe Research highlighted potential market share gains for Edwards due to a competitor's weaker data.
The company's Q4 financials showed a significant drop in net income (-76.35% YoY) and EPS (-75.38% YoY), despite revenue growth. Gross margin also declined slightly. Technical indicators and options data suggest bearish sentiment. No significant hedge fund or insider activity was observed.
In 2025/Q4, revenue increased by 13.26% YoY to $1.57 billion, but net income dropped significantly by 76.35% YoY to $91.2 million. EPS also fell by 75.38% YoY to $0.16, and gross margin decreased slightly to 78.15%.
Analysts have recently lowered price targets but maintain mostly Outperform or Buy ratings. Price targets range from $87 to $110, with the most recent adjustments reflecting cautious optimism ahead of Q1 earnings.
